ABL2

Across TCGA pan-cancer cohorts, ABL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ABL2 data layer compared with 29 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ABL2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ABL2 expression acts as an unfavorable survival marker, although some lineages such as GBM and UCEC show a favorable association.

CCRCC, GBM, and UCEC are the cancer types where ABL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.742	0.921	.004	43	view →
GBM	DFS	Median	All	0.870	0.619	.001	12	view →
UCEC	DFS	Tertile	All	1.000	0.904	.020	12	view →
LUAD	OS	Tertile	III,IV	1.000	0.300	.013	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ABL2–CCRCC (OS)

Open the CCRCC breakdown →